EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

TaiwanJ Pharmaceuticals Co., Ltd. (6549) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of TaiwanJ Pharmaceuticals Co., Ltd. TWD 0.84, price TWD 6.50, upside -87.1%, quality 46 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · TW · ISIN TW0006549009

TP Thin data Sep 24, 2026

TaiwanJ Pharmaceuticals Co., Ltd.

6549 · TWO

Weakest SetupStrongly overvalued and low quality.

!Fair value 0.8400 TWD · Strongly overvalued (−87%)
!Quality 46/100
!Mixed Growth (revenue YoY +48.1 %/yr)
!negative free cash flow
!Mixed vs. peers (4/7)
!Narrow moat 6/100
!Evidence only low, so the estimate is less certain
Watch TaiwanJ Pharmaceuticals Co., Ltd. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

9.32 TWD 6.30 TWD Fair Value 0.8400 TWD Dec 2025 Sep 2026

White line = price, green steps = our fair value per fiscal year. As of Sep 24, 2026.

How to read this chart

10‑month range 6.30 TWD – 9.32 TWD · fair‑value band 0.5500 TWD – 1.05 TWD · the 6.50 TWD price screens above the 0.8400 TWD fair value. As of Sep 24, 2026.

Follow TaiwanJ Pharmaceuticals Co. in your weekly email

Every Wednesday you see whether TaiwanJ Pharmaceuticals Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

TaiwanJ Pharmaceuticals Co., Ltd., a specialty pharmaceutical company, develops and commercializes small molecules for chronic organ inflammation of metabolic, autoimmune, and infectious etiologies in Taiwan. The company develops JKB-122 and JKB-121; and novel chemical entities for therapy to address chronic liver diseases and allergy/asthma.

Show more

TaiwanJ Pharmaceuticals Co., Ltd., a specialty pharmaceutical company, develops and commercializes small molecules for chronic organ inflammation of metabolic, autoimmune, and infectious etiologies in Taiwan. The company develops JKB-122 and JKB-121; and novel chemical entities for therapy to address chronic liver diseases and allergy/asthma. Its products target various diseases that include liver inflammation/liver fibrosis, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, autoimmune diseases, asthma, and atopic dermatitis. The company was incorporated in 2011 and is based in Zhubei, Taiwan.

Stock analysis

TaiwanJ Pharmaceuticals Co., Ltd. (6549) currently trades at 6.50 TWD, while our model-based Fair Value estimate is 0.8400 TWD, implying the stock looks roughly 674.0% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: 0.5500 TWD (bear) to 1.05 TWD (bull), the price of 6.50 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

TaiwanJ Pharmaceuticals Co., Ltd. reported revenue of 0 TWD in FY2025 versus 22.1M TWD in FY2021. Reported net income was −24.3M TWD in FY2025.

Key figures

Market cap 521M TWD (≈ $16.4M) · EPS (TTM) −0.3000 TWD · Return on equity −29.3% · Return on assets (EBIT) −39.0% · Free cash flow −24.5M TWD · Net cash 47.1M TWD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).

What moves the price

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −87%, 6549 screens richer than that median.

Fair Value models

Bear 0.5500 TWD Fair Value 0.8400 TWD Bull 1.05 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 0.4400 TWD 0.5900 TWD 0.8900 TWD 51
All 1 models by family
Asset-Based
NCAV (Graham) 0.4400 TWD 0.5900 TWD 0.8900 TWD 51

Open the full fair value analysis →

Notify me when 6549 reaches fair value

Put 6549 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 46/100

Of which business quality 48 · Market factors (momentum, volatility) 37

Profitability 0
Margins and returns on capital today
Quality Growth 25
Are margins and returns improving?
Cashflow 33
Earnings quality: real cash, not paper profit
Fin. Strength 100
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 69
Calm price path (market factor)
Momentum 30
Price trend over the last 3–12 months (market factor)
52W Momentum 12
Distance to the 52-week high (market factor)
Net Issuance 47
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 32/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−10.8% (2019) → −29.1% (2023)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

6549 screens 674% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Compare TaiwanJ Pharmaceuticals Co., Ltd. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 650 stocks

Beats the industry median on 4/6 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 48 · Above median
Fair Value upside −87% · Bottom 25%
Profitability
Return on assets −18% · Below median
Operating margin (TTM) 0% · Above median
Growth and dividend
Revenue growth 0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.23× · Cheapest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $516.34 $567.97 +10%
Regeneron Pharmaceuticals, Inc REGN $801.82 $1,252 +56%
argenx SE ARGX $963.79 $918.60 −5%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
CSL Limited CSL A$179.12 A$197.03 +10%
Alnylam Pharmaceuticals, Inc ALNY $251.65 $218.36 −13%
Royalty Pharma plc RPRX $58.52 $24.22 −59%
BeOne Medicines AG 6160 HK$218.20 HK$169.72 −22%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
BioNTech SE BNTX $100.87 $63.62 −37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

TaiwanJ Pharmaceuticals Co., Ltd. · Fair Value
0.8400 TWD −674%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "TaiwanJ Pharmaceuticals Co., Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/6549

Frequently asked questions

Is TaiwanJ Pharmaceuticals Co., Ltd. (6549) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 0.8400 TWD versus a price of 6.50 TWD, about −87% upside (overvalued).
What is the fair value of 6549?
Our model-based fair value for TaiwanJ Pharmaceuticals Co., Ltd. is 0.8400 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 6.50 TWD.
What is the quality score of 6549?
TaiwanJ Pharmaceuticals Co., Ltd. has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for TaiwanJ Pharmaceuticals Co., Ltd. (6549)?
Our model-based price target is the fair value of 0.8400 TWD (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 0.5500 TWD, optimistic scenario 1.05 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the TaiwanJ Pharmaceuticals Co., Ltd. stock forecast for 2026?
Our models put fair value at 0.8400 TWD, about −87% upside versus a price of 6.50 TWD (overvalued). Cautious scenario 0.5500 TWD, optimistic scenario 1.05 TWD. The calculation is refreshed regularly with new filings.
What is the intrinsic value of TaiwanJ Pharmaceuticals Co., Ltd. (6549)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For TaiwanJ Pharmaceuticals Co., Ltd. it is 0.8400 TWD per share (as of Sep 24, 2026), against a price of 6.50 TWD. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is TaiwanJ Pharmaceuticals Co., Ltd. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 6549 trades above its calculated fair value: price 6.50 TWD, fair value 0.8400 TWD, a gap of about −87% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6549?
No. The price is what the market pays today (6.50 TWD); the fair value is what the company's own numbers justify (0.8400 TWD). For TaiwanJ Pharmaceuticals Co., Ltd. the two are 5.66 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is TaiwanJ Pharmaceuticals Co., Ltd. worth?
The market values TaiwanJ Pharmaceuticals Co., Ltd. at about 521M TWD (market capitalisation, as of Sep 24, 2026). Per share that is 6.50 TWD; our models calculate a fair value of 0.8400 TWD per share.
What do the bullish and bearish scenarios say about 6549?
Our models span a range for TaiwanJ Pharmaceuticals Co., Ltd.: cautious scenario 0.5500 TWD, base 0.8400 TWD, optimistic 1.05 TWD per share (as of Sep 24, 2026, price 6.50 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of TaiwanJ Pharmaceuticals Co., Ltd. (6549)?
Balance-sheet figures for TaiwanJ Pharmaceuticals Co., Ltd. (as of Sep 24, 2026): return on equity −29.3%. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
Which stocks are comparable to TaiwanJ Pharmaceuticals Co., Ltd.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is TaiwanJ Pharmaceuticals Co., Ltd. stock attractive at the current price?
The data as of Sep 24, 2026: price 6.50 TWD, calculated fair value 0.8400 TWD (−87%), Quality Score 46/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6549 calculated?
We run TaiwanJ Pharmaceuticals Co., Ltd. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 0.8400 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. TaiwanJ Pharmaceuticals Co., Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of TaiwanJ Pharmaceuticals Co., Ltd. (6549)?
The closing price on Sep 24, 2026 was 6.50 TWD. Our model-based fair value is 0.8400 TWD, about −87% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with TaiwanJ Pharmaceuticals Co., Ltd. right now?
The price sits above even our optimistic bull case (1.05 TWD). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (46/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (0.5500 TWD to 1.05 TWD) leaves room in how you read the outcome.

Key figures of TaiwanJ Pharmaceuticals Co., Ltd.

How large is the market capitalisation of TaiwanJ Pharmaceuticals Co., Ltd. (6549)?
The market capitalisation of TaiwanJ Pharmaceuticals Co., Ltd. is 521M TWD (≈ $16.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of TaiwanJ Pharmaceuticals Co., Ltd. (6549)?
Earnings per share at TaiwanJ Pharmaceuticals Co., Ltd. are −0.3000 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of TaiwanJ Pharmaceuticals Co., Ltd. (6549)?
The return on equity (ROE) of TaiwanJ Pharmaceuticals Co., Ltd. is −29.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of TaiwanJ Pharmaceuticals Co., Ltd. (6549)?
On an EBIT basis the return on assets of TaiwanJ Pharmaceuticals Co., Ltd. is −39.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does TaiwanJ Pharmaceuticals Co., Ltd. (6549) generate?
The free cash flow of TaiwanJ Pharmaceuticals Co., Ltd. is −24.5M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does TaiwanJ Pharmaceuticals Co., Ltd. (6549) hold?
TaiwanJ Pharmaceuticals Co., Ltd. holds more cash than debt, 47.1M TWD net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch TaiwanJ Pharmaceuticals Co., Ltd. in the live analysis

One click puts TaiwanJ Pharmaceuticals Co., Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.